CN106999610A - 包含酰肼官能基团的靶向造影剂 - Google Patents

包含酰肼官能基团的靶向造影剂 Download PDF

Info

Publication number
CN106999610A
CN106999610A CN201580066846.8A CN201580066846A CN106999610A CN 106999610 A CN106999610 A CN 106999610A CN 201580066846 A CN201580066846 A CN 201580066846A CN 106999610 A CN106999610 A CN 106999610A
Authority
CN
China
Prior art keywords
contrast agent
metal
moiety
functional group
contrast
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201580066846.8A
Other languages
English (en)
Chinese (zh)
Inventor
继东·张
肯·柯里
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rf Medical
Original Assignee
Rf Medical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rf Medical filed Critical Rf Medical
Publication of CN106999610A publication Critical patent/CN106999610A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/106—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA
    • A61K49/108—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA the metal complex being Gd-DOTA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C243/00—Compounds containing chains of nitrogen atoms singly-bound to each other, e.g. hydrazines, triazanes
    • C07C243/24—Hydrazines having nitrogen atoms of hydrazine groups acylated by carboxylic acids
    • C07C243/38—Hydrazines having nitrogen atoms of hydrazine groups acylated by carboxylic acids with acylating carboxyl groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
CN201580066846.8A 2014-12-11 2015-12-10 包含酰肼官能基团的靶向造影剂 Pending CN106999610A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462090519P 2014-12-11 2014-12-11
US62/090,519 2014-12-11
US201562189414P 2015-07-07 2015-07-07
US62/189,414 2015-07-07
PCT/CA2015/051304 WO2016090491A1 (en) 2014-12-11 2015-12-10 Targeted contrast agents comprising a hydrazide functional group

Publications (1)

Publication Number Publication Date
CN106999610A true CN106999610A (zh) 2017-08-01

Family

ID=56106370

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580066846.8A Pending CN106999610A (zh) 2014-12-11 2015-12-10 包含酰肼官能基团的靶向造影剂

Country Status (6)

Country Link
US (1) US10286090B2 (enExample)
EP (1) EP3229848B1 (enExample)
JP (1) JP6796594B2 (enExample)
CN (1) CN106999610A (enExample)
CA (1) CA2968261C (enExample)
WO (1) WO2016090491A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110511176A (zh) * 2019-09-12 2019-11-29 陕西科技大学 双(2-邻苯二甲酰亚胺)胺及其制备方法
CN111606838A (zh) * 2020-06-19 2020-09-01 宁夏大学 一种双吲哚基甲烷类化合物的制备方法

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101864992B1 (ko) * 2017-03-09 2018-07-04 국립암센터 Mri 노이즈 제거용 조성물 및 이를 이용한 패드
CN107353258B (zh) * 2017-06-19 2019-09-24 南京科技职业学院 两种二核含钆磁共振成像对比剂及其制备与应用
CN111825703B (zh) * 2020-08-04 2023-06-23 江西司太立制药有限公司 一种钆贝葡胺注射液杂质的制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103547290A (zh) * 2011-04-20 2014-01-29 Rf医疗公司 靶向造影剂及其用途

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3621018A (en) 1968-06-28 1971-11-16 Hooker Chemical Corp 2,6-diketo-n-carboxymethylmorpholine
US5679810A (en) 1990-01-19 1997-10-21 Salutar, Inc. Linear oligomeric polychelant compounds
US6875864B2 (en) 1991-08-01 2005-04-05 Bracco International B.V. Aminocarboxylate ligands having substituted aromatic amide moieties
DE19744003B4 (de) * 1997-09-26 2004-07-08 Schering Ag Kontrastmittel für das Infarkt- und Nekroseimaging
US6093382A (en) 1998-05-16 2000-07-25 Bracco Research Usa Inc. Metal complexes derivatized with folate for use in diagnostic and therapeutic applications
EP0998946A1 (en) 1998-08-14 2000-05-10 K.U. Leuven Research & Development Non-porphyrin compound for use as a diagnosticum and/or pharmaceutical
US6146615A (en) 1999-01-11 2000-11-14 The University Of Toledo Contrast agents for image enhancement in magnetic resonance imaging
US6641797B2 (en) 2000-08-11 2003-11-04 Schering Aktiengesellschaft Perfluoroalkyl-containing complexes with sugar radicals, process for their production and their use
GB2368843A (en) 2000-11-08 2002-05-15 Leuven K U Res & Dev Non-porphyrin multipurpose contrast agents
AU2002218075A1 (en) 2000-11-08 2002-05-21 K.U. Leuven Research And Development Substituted bis-indole derivatives useful as contrast agents, pharmaceutical compositions containing them and intermediates for producing them
DE10105014C2 (de) 2001-01-26 2003-03-27 Schering Ag Neues Verfahren zur Herstellung von Monoamiden der DTPA
ATE411819T1 (de) * 2003-02-17 2008-11-15 Upperton Ltd Konjugate für medizinische abbildungen umfassend träger, targeting-anteile und kontrastmittel
GB0317467D0 (en) 2003-07-25 2003-08-27 Leuven K U Res & Dev Tissue infraction and necrosis specific compounds
WO2008088648A2 (en) * 2007-01-11 2008-07-24 Immunomedics, Inc. Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules
EP2651411B1 (en) 2010-12-13 2020-09-16 Immunomedics, Inc. Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103547290A (zh) * 2011-04-20 2014-01-29 Rf医疗公司 靶向造影剂及其用途

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
LUCA FRULLANO等: "Synthesis and Characterization of a Doxorubicin-Gd(III) Contrast Agent Conjugate: A New Approach toward Prodrug-Procontrast Complexes", 《INORGANIC CHEMISTRY》 *
张昌绍等: "《药理学 （第一卷）》", 31 August 1965, 人民卫生出版社 *
盛树力: "《老年痴呆发病机理与药物研究》", 31 October 2003, 科学技术文献出版社 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110511176A (zh) * 2019-09-12 2019-11-29 陕西科技大学 双(2-邻苯二甲酰亚胺)胺及其制备方法
CN111606838A (zh) * 2020-06-19 2020-09-01 宁夏大学 一种双吲哚基甲烷类化合物的制备方法
CN111606838B (zh) * 2020-06-19 2023-06-30 宁夏大学 一种双吲哚基甲烷类化合物的制备方法

Also Published As

Publication number Publication date
JP6796594B2 (ja) 2020-12-09
JP2018502150A (ja) 2018-01-25
CA2968261A1 (en) 2016-06-16
EP3229848A4 (en) 2018-07-18
EP3229848A1 (en) 2017-10-18
EP3229848B1 (en) 2020-08-12
US10286090B2 (en) 2019-05-14
WO2016090491A1 (en) 2016-06-16
US20170340757A1 (en) 2017-11-30
CA2968261C (en) 2021-08-17

Similar Documents

Publication Publication Date Title
US20140065075A1 (en) Targeted contrast agents and uses thereof
JP6896733B2 (ja) 二量体造影剤
JP6796594B2 (ja) 造影剤およびその用途
JP2003201258A (ja) 多座結合を介した多量体画像化剤の標的化
JP2018538294A (ja) 造影剤
CN108779082A (zh) 造影剂
WO2021127013A1 (en) Highly efficient myeloperoxidase activatable imaging agents
JP6087386B2 (ja) 造影剤としてのｎ−アルコキシアミド抱合体
JP2004526671A (ja) 診断および治療への適用において使用するための抗酸化剤の金属キレート配位子との結合体
JP6826989B2 (ja) エチレンジアミン四酢酸ビス（アミド）誘導体およびＭＲＩ造影剤としての使用のためのそれらのＭｎ（ＩＩ）イオンとの錯体
WO2022241470A9 (en) Molecular probes for in vivo detection of aldehydes
NL2033714B1 (en) Multiplexing targeting and imaging agents
WO2025044924A1 (zh) 靶向碳酸酐酶放射性药物
WO2025124439A1 (zh) Fap靶向放射性药物
BR112017026135B1 (pt) Compostos de quelato de gadolínio, seus intermediários, seus usos e seu método de preparação, e método para geração de imagem de tecido corporal em um paciente
HK1200823B (en) N-alkoxyamide conjugates as imaging agents

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20170801

RJ01 Rejection of invention patent application after publication